Dr. David Berglund and Dr. Stephen Wooding nominated as new board members at XNK Therapeutics
XNK Therapeutics AB (“XNK”) today announced that Dr. David Berglund and Dr. Stephen Wooding are proposed to be appointed members of the Board of Directors. The decision will be taken at an extra…
XNK Therapeutics appoints Markus Thor as Chief Business Officer
XNK Therapeutics AB (“XNK”) today announced the appointment of Markus Thor as Chief Business Officer, effective September 6th. He will be member of the company’s management team. Mr….
XNK Therapeutics lays the groundwork for GMP facility to meet growth plans
After an intensive spring with preparation, planning, procurement, and design, the groundwork was laid for constructing a GMP facility that enables the aseptic production of ATMPs and clinical…
XNK Therapeutics Reports First Patient Included in Phase II Study in Multiple Myeloma
XNK Therapeutics AB (“XNK”) today announced that the first patient has been included in a Phase II clinical study to treat patients with Multiple myeloma using XNK’s leading autologous natural…
Report from Annual General Meeting in XNK Therapeutics AB (publ)
XNK Therapeutics AB (publ) today held its Annual General Meeting. The annual general meeting was held through advance voting (postal voting) in accordance with temporary legislation. The following…
XNK Therapeutics appoints Michael Uhlin as Chief Scientific Officer
XNK Therapeutics AB (“XNK”) today announced the appointment of Professor Michael Uhlin as Chief Scientific Officer, effective August 1st. He will be a member of the company’s…
XNK Therapeutics appoints Dr. Johan Aschan as Chief Medical Officer
XNK Therapeutics AB (“XNK”) today announced the appointment of Dr. Johan Aschan as Chief Medical Officer, effective July 1st. He will be member of the company’s management team. Dr….
XNK Therapeutics completes private placement of SEK 64 million
XNK Therapeutics AB (“XNK” or the “Company”), a Swedish clinical stage immunotherapy company treating cancer by developing novel NK cell-based therapies, today announced the completion of a…
Resolution from extraordinary general meeting in XNK Therapeutics
XNK Therapeutics AB (“XNK”) held an extraordinary general meeting on March 18, 2021, where the general meeting resolved to change the company category from private to public limited company. The…
XNK partners with KI on Phase II study in MM with support from Sanofi
XNK Therapeutics AB (“XNK”) today announced that it is entering into a joint Phase II clinical study to treat patients with multiple myeloma using XNK’s leading drug candidate in combination…